Literature DB >> 26005702

Implications of scavenger receptors in the safe development of nanotherapeutics.

Jonathan H Shannahan1, Wei Bai1, Jared M Brown1.   

Abstract

Nanomaterials (NMs) are being utilized in a variety of biomedical applications including drug delivery, diagnostics, and therapeutic targeting. These applications are made possible due to the unique physicochemical properties that are exhibited at the nanoscale. To ensure safe development of NMs for clinical use, it is necessary to understand their interactions with cells and specifically cell surface receptors, which will facilitate either their toxicity and/or clinical function. Recently our research and others have investigated the role of scavenger receptors in mediating NM-cell interactions and responses. Scavenger receptors are expressed by a variety of cell types that are first to encounter NMs during clinical use such as macrophages and endothelial cells. Scavenger receptors are recognized to facilitate uptake of a wide variety of ligands ranging from foreign substances to endogenous lipids/proteins. While interaction of NMs with scavenger receptors may allow therapeutic targeting in some instances, it also presents a challenge for the stealth delivery of NMs and avoidance of the scavenging capability of this class of receptors. Due to their role in facilitating immune responses, scavenger receptor-mediated inflammation is also of concern following NM delivery. The research highlighted in this brief review intends to summarize our current understanding regarding the consequences of NM-scavenger receptor interactions.

Entities:  

Keywords:  CD36; MARCO; Macrophage; Mast Cell; Nanomedicine; Nanoparticle; Nanotoxicology; SR-A; SR-B1

Year:  2015        PMID: 26005702      PMCID: PMC4437212          DOI: 10.14800/rci.811

Source DB:  PubMed          Journal:  Receptors Clin Investig


  33 in total

Review 1.  Scavenger receptor class B type I: a multifunctional receptor.

Authors:  Giuseppe Valacchi; Claudia Sticozzi; Yunsook Lim; Alessandra Pecorelli
Journal:  Ann N Y Acad Sci       Date:  2011-07       Impact factor: 5.691

Review 2.  [The role of the class A scavenger receptors, SR-A and MARCO, in the immune system. Part 2. Contribution to recognition and phagocytosis of pathogens as well as induction of immune response].

Authors:  Szczepan Józefowski
Journal:  Postepy Hig Med Dosw (Online)       Date:  2012-02-29       Impact factor: 0.270

3.  A carbon nanotube toxicity paradigm driven by mast cells and the IL-₃₃/ST₂ axis.

Authors:  Pranita Katwa; Xiaojia Wang; Rakhee N Urankar; Ramakrishna Podila; Susana C Hilderbrand; Robert B Fick; Apparao M Rao; Pu Chun Ke; Christopher J Wingard; Jared M Brown
Journal:  Small       Date:  2012-07-06       Impact factor: 13.281

4.  A murine scavenger receptor MARCO recognizes polystyrene nanoparticles.

Authors:  Sanae Kanno; Akiko Furuyama; Seishiro Hirano
Journal:  Toxicol Sci       Date:  2007-03-14       Impact factor: 4.849

Review 5.  Nanomedicines for antimicrobial interventions.

Authors:  F Cavalieri; M Tortora; A Stringaro; M Colone; L Baldassarri
Journal:  J Hosp Infect       Date:  2014-10-02       Impact factor: 3.926

6.  Direct recognition of superparamagnetic nanocrystals by macrophage scavenger receptor SR-AI.

Authors:  Ying Chao; Priya P Karmali; Rajesh Mukthavaram; Santosh Kesari; Valentina L Kouznetsova; Igor F Tsigelny; Dmitri Simberg
Journal:  ACS Nano       Date:  2013-04-30       Impact factor: 15.881

7.  A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism.

Authors:  A Rigotti; B L Trigatti; M Penman; H Rayburn; J Herz; M Krieger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

8.  Recognition of dextran-superparamagnetic iron oxide nanoparticle conjugates (Feridex) via macrophage scavenger receptor charged domains.

Authors:  Ying Chao; Milan Makale; Priya Prakash Karmali; Yuriy Sharikov; Igor Tsigelny; Sergei Merkulov; Santosh Kesari; Wolf Wrasidlo; Erkki Ruoslahti; Dmitri Simberg
Journal:  Bioconjug Chem       Date:  2012-04-26       Impact factor: 4.774

9.  Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles.

Authors:  Mian M K Shahzad; Lingegowda S Mangala; Hee Dong Han; Chunhua Lu; Justin Bottsford-Miller; Masato Nishimura; Edna M Mora; Jeong-Won Lee; Rebecca L Stone; Chad V Pecot; Duangmani Thanapprapasr; Ju-Won Roh; Puja Gaur; Maya P Nair; Yun-Yong Park; Nirupama Sabnis; Michael T Deavers; Ju-Seog Lee; Lee M Ellis; Gabriel Lopez-Berestein; Walter J McConathy; Laszlo Prokai; Andras G Lacko; Anil K Sood
Journal:  Neoplasia       Date:  2011-04       Impact factor: 5.715

10.  Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells.

Authors:  Jeffrey D McCurdy; Timothy J Olynych; Lauren H Maher; Jean S Marshall
Journal:  J Immunol       Date:  2003-02-15       Impact factor: 5.422

View more
  14 in total

1.  Experimental challenges regarding the in vitro investigation of the nanoparticle-biocorona in disease states.

Authors:  Sherleen Xue-Fu Adamson; Zhoumeng Lin; Ran Chen; Lisa Kobos; Jonathan Shannahan
Journal:  Toxicol In Vitro       Date:  2018-05-05       Impact factor: 3.500

Review 2.  Nanovaccines for cancer immunotherapy.

Authors:  Yu Zhang; Shuibin Lin; Xiang-Yang Wang; Guizhi Zhu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-06-06

Review 3.  Unintended effects of drug carriers: Big issues of small particles.

Authors:  Hamideh Parhiz; Makan Khoshnejad; Jacob W Myerson; Elizabeth Hood; Priyal N Patel; Jacob S Brenner; Vladimir R Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2018-07-03       Impact factor: 15.470

Review 4.  The delivery of therapeutic oligonucleotides.

Authors:  Rudolph L Juliano
Journal:  Nucleic Acids Res       Date:  2016-04-15       Impact factor: 16.971

5.  Biomimetic Nanoparticle Vaccines for Cancer Therapy.

Authors:  Ashley V Kroll; Yao Jiang; Jiarong Zhou; Maya Holay; Ronnie H Fang; Liangfang Zhang
Journal:  Adv Biosyst       Date:  2018-11-13

6.  The biocorona: a challenge for the biomedical application of nanoparticles.

Authors:  Jonathan Shannahan
Journal:  Nanotechnol Rev       Date:  2017-01-20       Impact factor: 7.848

7.  From the Cover: Disease-Induced Disparities in Formation of the Nanoparticle-Biocorona and the Toxicological Consequences.

Authors:  Jonathan H Shannahan; Kristofer S Fritz; Achyut J Raghavendra; Ramakrishna Podila; Indushekar Persaud; Jared M Brown
Journal:  Toxicol Sci       Date:  2016-06-02       Impact factor: 4.849

Review 8.  Environmental Immunology: Lessons Learned from Exposure to a Select Panel of Immunotoxicants.

Authors:  Joanna M Kreitinger; Celine A Beamer; David M Shepherd
Journal:  J Immunol       Date:  2016-04-15       Impact factor: 5.422

Review 9.  Emerging Advances of Nanotechnology in Drug and Vaccine Delivery against Viral Associated Respiratory Infectious Diseases (VARID).

Authors:  Amir Seyfoori; Mahdieh Shokrollahi Barough; Pooneh Mokarram; Mazaher Ahmadi; Parvaneh Mehrbod; Alireza Sheidary; Tayyebeh Madrakian; Mohammad Kiumarsi; Tavia Walsh; Kielan D McAlinden; Chandra C Ghosh; Pawan Sharma; Amir A Zeki; Saeid Ghavami; Mohsen Akbari
Journal:  Int J Mol Sci       Date:  2021-06-28       Impact factor: 5.923

10.  Impact of Silver and Iron Nanoparticle Exposure on Cholesterol Uptake by Macrophages.

Authors:  Jonathan H Shannahan; Hari Sowrirajan; Indushekhar Persaud; Ramakrishna Podila; Jared M Brown
Journal:  J Nanomater       Date:  2015       Impact factor: 2.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.